🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesMy blood pressure normalization journey — July 2024 Page 3

My blood pressure normalization journey — July 2024

JessicaH_TX Sat, Aug 16, 2025 at 1:11 PM 25 replies 1,700 viewsPage 3 of 5
BariatricNurseD
Senior Member
1,678
7,234
Feb 2024
Dallas, TX
Online
Aug 21, 2025 at 4:49 AM#11
Dr.RaviCardio said:
Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…
Dr.RaviCardio said:
...cardiovascular risk is just another fad...

I understand the skepticism — we've all seen "miracle" weight loss solutions come and go. But consider what makes GLP-1 agonists different:

  • Phase 3 RCTs with thousands of participants (not 20-person pilot studies)
  • Published in NEJM, JAMA, Lancet (not press releases)
  • Replicated across multiple independent research groups
  • Proven cardiovascular and renal benefits beyond weight loss
  • Biological mechanism fully characterized at the receptor level

This isn't a fad — it's a new drug class supported by the highest level of clinical evidence. The comparison to past fads is understandable but inappropriate.

Last edited: Aug 21, 2025 at 9:49 AM
8 8tony_orlando, Dr.NephBHM_UK, kim_atl_prep and 5 others
Reply Quote Save Share Report
TomTeleRx
Member
189
678
Feb 2025
Delaware
Aug 23, 2025 at 5:16 PM#12
Dr.SleepRoch said:
Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated…

Thank you for spelling out the reasoning rather than just the conclusion.

7 7bri_stats, pete_manc_UK, anna.melb_AU and 4 others
Reply Quote Save Share Report
SaraMom3
Member
456
2,345
Aug 2024
Ohio
Aug 26, 2025 at 5:44 AM#13
Dr.RaviCardio said:
Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…

CRP reduction on cardiovascular risk — this is the lab result that excites me most:

Baseline hsCRP: 7.0 mg/L (high cardiovascular risk)
Month 6 hsCRP: 1.5 mg/L (moderate risk)
Month 12 hsCRP: 0.3 mg/L (low risk)

This level of inflammatory marker reduction is comparable to what you'd see with statin therapy. Combined with the weight loss, my 10-year ASCVD risk score dropped from 14% to 4%. My cardiologist is genuinely impressed.

6 6KetoKyle, CanadaChris, ZaraB_AL and 3 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
quinn_sf
Member
489
2,123
Jun 2024
San Francisco, CA
Aug 28, 2025 at 6:14 PM#14
JessicaH_TX said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Senior perspective on cardiovascular risk: I'm 63 years old and started this journey skeptically. My endocrinologist recommended it after years of failed interventions.

15 months later: down 46 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

Last edited: Aug 29, 2025 at 12:14 AM
5 5andrew_nyc, Dr.EndoEP, GraceAZ_72 and 2 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Aug 31, 2025 at 6:45 AM#15

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. No action needed from anybody.

4 4PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 1 other
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register